■肾母细胞瘤(WT)是由胚胎肾发育异常引起的,与short,称为microRNAs(miRNAs)的非蛋白质编码RNA。目前,没有可靠的WT循环生物标志物,这仍然是一个迫切的未满足的临床需求。这些生物标志物可以帮助诊断,亚型/预测,和疾病监测。这里,我们从现有已发表的文献中建立了WT中循环miRNA失调的列表.
■无论发布日期如何,PubMed,Scopus,Web-of-Science,和Wiley在线文库数据库被搜索用于WT循环miRNA的英语/法语研究。符合PRISMA的搜索已在PROSPERO中注册。QUADAS工具测量保留的物品质量。荟萃分析评估了miRNA对WT诊断的敏感性和特异性。
■定性分析包括来自450篇已发表的文章中的5篇的280个样本(172例WT患者;108例健康对照)。该研究发现了301个失调的miRNA(144个上调,143下调,14冲突)。汇集的敏感性,特异性,来自两项研究的49个显著失调的microRNAs的AUC为0.67[0.62;0.73],分别为0.95[0.92;0.96]和0.77[0.73;0.81],表明WT具有更强的诊断潜力。
■循环miRNA显示出有望用于WT诊断和预后。需要更多的研究来证实这些发现并确定与肿瘤分期/亚型的关联。
■CRD42022301597。
UNASSIGNED: Wilms tumour (
WT) is caused by aberrant embryonic kidney development and associated with dysregulated expression of short, non-protein-coding RNAs termed microRNAs (miRNAs). At present, there is no reliable circulating biomarker of
WT, and this remains an urgent unmet clinical need. Such biomarkers may assist diagnosis, subtyping/prognostication, and disease-monitoring. Here, we established the list of dysregulated circulating miRNAs in WT from the existing published literature.
UNASSIGNED: Regardless of publication date, PubMed, Scopus, Web-of-Science, and Wiley online library databases were searched for English/French studies on WT circulating miRNAs. The PRISMA-compliant search was registered in PROSPERO. The QUADAS tool measured retained article quality. The meta-analysis assessed the sensitivity and specificity of miRNAs for
WT diagnosis.
UNASSIGNED: Qualitative analysis included 280 samples (172
WT patients; 108 healthy controls) from five of 450 published articles. The study uncovered 301 dysregulated miRNAs (144 up-regulated, 143 down-regulated, 14 conflicting). The pooled sensitivity, specificity, and AUC of the 49 significantly dysregulated microRNAs from two studies was 0.67 [0.62; 0.73], 0.95 [0.92; 0.96] and 0.77 [0.73; 0.81] respectively, indicating a stronger diagnostic potential for WT.
UNASSIGNED: Circulating miRNAs show promise for
WT diagnosis and prognosis. More research is needed to confirm these findings and determine associations with tumour stage/subtype.
UNASSIGNED: CRD42022301597.